Vivek Dhar Dwivedi

Dr. Vivek Dhar Dwivedi

Pathfinder Research and Training Foundation
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
SBShiv Bharadwaj
Shiv Bharadwaj
ADAmit Dubey
Amit Dubey
UYUmesh Yadava
Umesh Yadava
SMSarad Kumar Mishra
Sarad Kumar Mishra
SKSang G. Kang
Sang G. Kang
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a dreaded pandemic in lack of specific therapeutic agent. SARS-CoV-2 Mpro, an essential factor in viral pathogenesis, is recognized as a prospective therapeutic target in drug discovery against SARS-CoV-2. To tackle this pandemic, Food and Drug Administration-approved drugs are being screened against SARS-CoV-2 Mpro via in silico and in vitro methods to detect the best conceivable drug candidates. However, identification of natural compounds with anti-SARS-CoV-2 Mpro potential have been recommended as rapid and effective alternative for anti-SARS-CoV-2 therapeutic development. Thereof, a total of 653 natural compounds were identified against SARS-CoV-2 Mpro from NP-lib database at MTi-OpenScreen webserver using virtual screening approach. Subsequently, top four potential compounds, i.e. 2,3-Dihydroamentoflavone (ZINC000043552589), Podocarpusflavon-B (ZINC000003594862), Rutin (ZINC000003947429) and Quercimeritrin 6”-O-L-arabinopyranoside (ZINC000070691536), and co-crystallized N3 inhibitor as reference ligand were considered for stringent molecular docking after geometry optimization by DFT method. Each compound exhibited substantial docking energy >−12 kcal/mol and molecular contacts with essential residues, including catalytic dyad (His41 and Cys145) and substrate binding residues, in the active pocket of SARS-CoV-2 Mpro against N3 inhibitor. The screened compounds were further scrutinized via absorption, distribution, metabolism, and excretion - toxicity (ADMET), quantum chemical calculations, combinatorial molecular simulations and hybrid QM/MM approaches. Convincingly, collected results support the potent compounds for druglikeness and strong binding affinity with the catalytic pocket of SARS-CoV-2 Mpro. Hence, selected compounds are advocated as potential inhibitors of SARS-CoV-2 Mpro and can be utilized in drug development against SARS-CoV-2 infection.

13 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SBShiv Bharadwaj
Shiv Bharadwaj
KLKyung Eun Lee
Kyung Eun Lee
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
Umesh YadavaUmesh Yadava
Umesh Yadava
APAleksha Panwar
Aleksha Panwar
SKSang G. Kang
Sang G. Kang
Dengue virus (DENV) infection causes serious health problems in humans for which no drug is currently available. Recently, DENV NS2B-NS3 protease has been proposed as a primary target for anti-dengue drug discovery due to its important role in new virus particle formation by conducting DENV polyprotein cleavage. Triterpenoids from the medicinal fungus Ganoderma lucidum have been suggested as pharmacologically bioactive compounds and tested as anti-viral agents against various viral pathogens including human immunodeficiency virus. However, no reports are available concerning the anti-viral activity of triterpenoids from Ganoderma lucidum against DENV. Therefore, we employed a virtual screening approach to predict the functional triterpenoids from Ganoderma lucidum as potential inhibitors of DENV NS2B-NS3 protease, followed by an in vitro assay. From in silico analysis of twenty-two triterpenoids of Ganoderma lucidum, four triterpenoids, viz. Ganodermanontriol (−6.291 kcal/mol), Lucidumol A (−5.993 kcal/mol), Ganoderic acid C2 (−5.948 kcal/mol) and Ganosporeric acid A (−5.983 kcal/mol) were predicted to be viral protease inhibitors by comparison to reference inhibitor 1,8-Dihydroxy-4,5-dinitroanthraquinone (−5.377 kcal/mol). These results were further studied for binding affinity and stability using the molecular mechanics/generalized Born surface area method and Molecular Dynamics simulations, respectively. Also, in vitro viral infection inhibition suggested that Ganodermanontriol is a potent bioactive triterpenoid.

Verified
Journal Article
Open access
PDF file
RKRidhima Kaul
Ridhima Kaul
PPPradipta Paul
Pradipta Paul
Sanjay KumarSanjay Kumar
Sanjay Kumar
Dietrich BüsselbergDietrich Büsselberg
Dietrich Büsselberg
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
ACAli CHAARI
Ali CHAARI
The ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a globally leading public health concern over the past two years. Despite the development and administration of multiple vaccines, the mutation of newer strains and challenges to universal immunity has shifted the focus to the lack of efficacious drugs for therapeutic intervention for the disease. As with SARS-CoV, MERS-CoV, and other non-respiratory viruses, flavonoids present themselves as a promising therapeutic intervention given their success in silico, in vitro, in vivo, and more recently, in clinical studies. This review focuses on data from in vitro studies analyzing the effects of flavonoids on various key SARS-CoV-2 targets and presents an analysis of the structure-activity relationships for the same. From 27 primary papers, over 69 flavonoids were investigated for their activities against various SARS-CoV-2 targets, ranging from the promising 3C-like protease (3CLpro) to the less explored nucleocapsid (N) protein; the most promising were quercetin and myricetin derivatives, baicalein, baicalin, EGCG, and tannic acid. We further review promising in silico studies featuring activities of flavonoids against SARS-CoV-2 and list ongoing clinical studies involving the therapeutic potential of flavonoid-rich extracts in combination with synthetic drugs or other polyphenols and suggest prospects for the future of flavonoids against SARS-CoV-2.

1 September 2020 in Life Sciences
Verified
Journal Article
Closed access
SBShiv Bharadwaj
Shiv Bharadwaj
KLKyung Eun Lee
Kyung Eun Lee
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
SKSang G. Kang
Sang G. Kang

2 June 2022 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SKSanjay Kumar
Sanjay Kumar
AVAkanksha Verma
Akanksha Verma
PYPardeep Yadav
Pardeep Yadav
SDSumit Kumar Dubey
Sumit Kumar Dubey
Esam AzharEsam Azhar
Esam Azhar
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi

30 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AHAhmed Hassan
Ahmed Hassan
HGHattan Gattan
Hattan Gattan
AFArwa Ali Faizo
Arwa Ali Faizo
MAMohammed H. Alruhaili
Mohammed H. Alruhaili
AAAzzah Alharbi
Azzah Alharbi
Esam AzharEsam Azhar
Esam Azhar
Background/Objectives: Monkeypox is a re-emerging viral disease with features of infectiously transmitted zoonoses. It is now considered a public health priority because of its rising incidence and transmission from person to person. Monkeypox virus (MPXV) VP39 protein is identified as an essential protein for replication of the virus, and therefore, it is a potential target for antiviral drugs. Methods: This work analyzes the binding affinities and the differential conformational stability of three target compounds and one control compound with the VP39 protein through multiple computational methods. Results: The re-docking analysis revealed that the compounds had high binding affinities towards the target protein; among these compounds, compounds 1 and 2 showed the highest binding energies in the virtual screening, and thus, these were considered as the most active inhibitor candidates. Intermolecular interaction analysis revealed distinct binding mechanisms. While compound 1 had very strong hydrogen bonds and hydrophobic interactions, compound 2 had numerous water-mediated interactions, and compound 3 had only ionic and hydrophobic contacts. In molecular dynamic simulations, compounds 1 and 2 showed that the protein–ligand complexes had a stable conformation, with protein RMSD values around 2 Å for both compounds. In contrast, compound 3 was slightly flexible, and the control compound was more flexible. MM/GBSA analysis again supported these results, which gave the binding free energies that were also supportive for these compounds. Conclusions: Notably, all the selected compounds, especially compounds 1 and 2, demonstrate high binding affinity. Therefore, these compounds can be further tested as antiviral agents against monkeypox treatment.